by Nathalie Rolhion, Harry Sokol
Antibiotic treatments can profoundly disrupt gut microbiome structure and function. This article reviews new findings showing how Saccharomyces boulardii CNCM I-745 helps preserve microbial activity and metabolic resilience during antibiotic stress, with insights from advanced in vitro models and immune assays.
by Karen Madsen
Previous clinical studies have shown a promising role of fecal microbiota transplantation to induce remission in ulcerative colitis and maintain steroid-induced Crohn’s disease remission. A new double-blind, placebo-controlled trial found fecal microbiota transplantation is not effective at inducing clinical or endoscopic remission in adults with Crohn’s disease.
The 6th biennial meeting of the European Society of Neurogastroenterology and Motility, held at Queen Mary University of London, UK, from 4-6 September 2025, covered basic, translational, and clinical research in neurogastroenterology, including dietary therapies and ‘biotics’ for the management of gastrointestinal disorders. Find out more about the main takeaways from the conference.
by Konstantina Zafeiropoulou
Crohn’s disease is an immune-mediated disease without a cure. While current guideline-based therapies are immune-directed therapies (small molecules and biologics), recent advances in understanding how the gut microbiome changes precede and drive disease offer potential for developing personalized therapeutics.
by Premysl Bercik
While the gut microbiome differs between patients with IBS and healthy controls, the precise mechanisms underlying the initial phase of microbial-host interactions are not fully understood. New findings in mice identify a critical role of intestinal dendritic cells’ activation and migration in impacting brain neuroplasticity.
Emerging research suggests a complex interaction between the gut microbiome and endometriosis. Recent studies have begun to explore the impact of dietary interventions on endometriosis.
by Andreu Prados
The 13th Gut Microbiota for Health World Summit took place 15-16 March 2025 in Washington, D.C., and it focused on advances in microbiome research to diagnose, prevent, and manage gastrointestinal and extra-intestinal conditions. Find out more about the most valuable takeaways from the event.
by Andreu Prados
As antibiotic-resistant infections continue to rise worldwide, phage therapy emerges as a promising alternative to antibiotics to tackle this public health threat.
by Francesco Broccolo
As it becomes evident that the microbiome impacts the function of the human immune system, scientists have begun to leverage intestinal microbes to reduce harmful inflammation, fight some tumors, and prevent diseases.
With the advancement of medicine, our population is undergoing a prolonged aging process. Over the next three decades, the global population aged over 65 years is set to more than double, reaching a staggering 1.5 billion individuals. The emergence of the gut microbiota as a potent modulator of healthy aging requires a concerted effort to allocate resources and research towards developing interventions aimed at promoting optimal gut health and longevity.
